Literature DB >> 11346029

The botulinum toxins in the treatment of cervical dystonia.

A Brashear1.   

Abstract

The use of botulinum toxin to treat cervical dystonia (CD) has dramatically improved the quality of life of patients with this disabling, often painful disease. Two forms of toxins, botulinum toxin type A (BTX-A) and botulinum toxin type B (BTX-B), have each been studied in large multicenter trials in subjects with CD. A study of BTX-A demonstrated improvement of 5.15 to 10.65 degrees in head position using the Cervical Dystonia Severity Scale (CDSS) in those treated with BTX-A (trade name BOTOX) compared with placebo. A study in patients who continued to respond to BTX-A and a similarly designed study in patients who were resistant to BTX-A demonstrated statistical improvement in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) in those treated with BTX-B (evaluated as NeuroBloc) compared with placebo. The potential availability of both forms of toxin will allow physicians to offer further treatment options to patients with CD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11346029     DOI: 10.1055/s-2001-13123

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  5 in total

1.  Selective peripheral denervation for cervical dystonia: long-term follow-up.

Authors:  A Tommy Bergenheim; Erik Nordh; Eva Larsson; Marwan I Hariz
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-10-31       Impact factor: 10.154

2.  Quality of life in cervical dystonia after treatment with botulinum toxin A: a 24-week prospective study.

Authors:  Subsai Kongsaengdao; Benchalak Maneeton; Narong Maneeton
Journal:  Neuropsychiatr Dis Treat       Date:  2017-01-10       Impact factor: 2.570

3.  Long-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study.

Authors:  Subsai Kongsaengdao; Narong Maneeton; Benchalak Maneeton
Journal:  Neuropsychiatr Dis Treat       Date:  2018-04-26       Impact factor: 2.570

4.  Low-Dose Neubotulinum Toxin A versus Low-Dose Abobotulinum Toxin A Injection for the Treatment of Cervical Dystonia: A Multicenter, 48-Week, Prospective, Double-Blinded, Randomized Crossover Design Study.

Authors:  Subsai Kongsaengdao; Arkhom Arayawithchanont; Kanoksri Samintharapanya; Pichai Rojanapitayakorn; Benchalak Maneeton; Narong Maneeton
Journal:  Toxins (Basel)       Date:  2021-10-01       Impact factor: 4.546

5.  Botulinum toxin type A in the treatment of patients with cervical dystonia.

Authors:  Allison Brashear
Journal:  Biologics       Date:  2009-07-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.